BT 123
Alternative Names: BT-123Latest Information Update: 25 Aug 2023
At a glance
- Originator ScinnoHub Pharmaceutical
- Class Antineoplastics; Immunotherapies; RNA
- Mechanism of Action RNA splicing modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 14 Jul 2023 Early research in Cancer in China (ScinnoHub Pharmaceutical pipeline, July 2023)